Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LED Device for Non-Invasive Lipolysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03171051
Recruitment Status : Terminated (device development placed on hold)
First Posted : May 31, 2017
Results First Posted : October 14, 2020
Last Update Posted : November 9, 2020
Sponsor:
Information provided by (Responsible Party):
Venus Concept

Brief Summary:
This study is being conducted to evaluate the ability of a light emitting diode (LED) study device's ability to raise the temperatures on flank tissue to a similar level compared to an approved laser device (SculpSure by Cynosure). Laser treatments have been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.

Condition or disease Intervention/treatment Phase
Lipolysis Device: 950 nm LED Device Device: 1050nm Diode Laser Device Not Applicable

Detailed Description:
This is an open-label, feasibility study comparing the tissue temperature profile of a 950 nm LED device and a 1060 nm diode laser for non-invasive lipolysis of the flanks. The study will enroll up to 10 subjects requesting non-invasive lipolysis of the flanks. Each subject will receive a single treatment with each device on opposite flanks. Tissue temperatures in the treated areas will be recorded at various tissue depths and compared. Subjects will be asked to assess their discomfort and pain of the study treatment using a 10 cm visual analog scale (VAS). In addition, the safety (number of treatment related adverse events) of the LED device will be compared to the reference device at the time of treatment and one week later.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: All subjects to receive the same treatments - right flank of abdomen with the experimental LED device and the left flank of the abdomen with the active comparator diode laser device.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Feasibility Study of a 950 nm Wavelength LED Device for Non-Invasive Lipolysis of the Flanks
Actual Study Start Date : June 1, 2017
Actual Primary Completion Date : May 16, 2019
Actual Study Completion Date : May 16, 2019

Arm Intervention/treatment
Lipolysis treatment

The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.

The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.

Device: 950 nm LED Device
Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.

Device: 1050nm Diode Laser Device
FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
Other Name: SculpSure




Primary Outcome Measures :
  1. Temperature Profile Comparison of the LED Device as Compare to the Reference Device (Diode Laser) at Various Tissue Depths [ Time Frame: At time of treatment ]
    Immediately (within 2 minutes) after treatment of the area, 3 sterile thermocouple needles of different lengths (9.5-14 mm), will be inserted into the center of each applicator footprint. Temperature readings from each thermocouple needle will be recorded.


Secondary Outcome Measures :
  1. Visual Analog Scale (VAS) [ Time Frame: Time of treatment ]
    Subjects reported level of discomfort and pain after treatment with LED and Laser applicators on a 10 cm horizontal line on which the patient's pain intensity is represented by a point between the extremes of 'no pain at all' (value of 0 cm) and 'worst pain imaginable' (value of 10 cm).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult, male or female, ≥ 18 years of age or older with skin types 1-VI.
  • Having moderate excess bilateral fatty tissue of the flanks, suitable area for non-invasive lipolysis.
  • Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control for at least three months prior to enrolment and throughout the course of the study and have a negative urine pregnancy test at baseline.

Exclusion Criteria:

  • Pregnant, expectation of pregnancy, postpartum or nursing (<6 months).
  • History of skin disease in the area to be treated over the last 6 months.
  • Previous surgical intervention to the treatment area.
  • History of skin cancer or pre-cancerous lesions at the treatment areas.
  • Having any electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
  • History of immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications;
  • Uncontrolled systemic diseases such as diabetes.
  • Active infections in the treatment area.
  • History of dysplastic nevi.
  • Significant concurrent skin conditions or any inflammatory skin conditions.
  • Active herpes simplex infections (e.g. cold sores), open lacerations or abrasions in the treatment area.
  • Chronic or cutaneous viral, fungal, or bacterial diseases.
  • Use of Accutane™ (Isotretinoin) within the past six months.
  • Keloid or hypertrophic scar formation in the treatment area.
  • Tattoos in the treatment area.
  • History of auto-immune disorders.
  • Erythema abigne, when identified treatments should be discontinued.
  • History of photosensitivity disorder that can be exacerbated by laser or intense light.
  • Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light.
  • History of poor wound healing in the treatment area.
  • Sunburns.
  • Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation.
  • Prior skin treatment with laser or other devices on the same treatment area within the last six months prior to study enrollment or during the course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03171051


Locations
Layout table for location information
United States, New York
Sadick Research Group
New York, New York, United States, 10075
Sponsors and Collaborators
Venus Concept
Investigators
Layout table for investigator information
Study Director: Yoni Iger, PhD Venus Concept Ltd.
  Study Documents (Full-Text)

Documents provided by Venus Concept:
Layout table for additonal information
Responsible Party: Venus Concept
ClinicalTrials.gov Identifier: NCT03171051    
Other Study ID Numbers: CS0117
First Posted: May 31, 2017    Key Record Dates
Results First Posted: October 14, 2020
Last Update Posted: November 9, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: This is a feasibility study. Sharing of IPD may occur if the study supports further development of the device.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes